Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing

For decades, biopharma companies evaluating outsourced manufacturing faced a binary choice. They could lease facility space and build the surrounding operations themselves, or they could outsource the entire effort to a contract development and manufacturing organization (CDMO). Both options worked, but neither was particularly well-suited to the realities of how emerging biopharma companies actually develop and manufacture today.